Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer

Background: This retrospective single-center cohort study evaluated the efficacy and safety of a combination of neoadjuvant luteinizing hormone-releasing hormone (LHRH) antagonist and tegafur-uracil (UFT) therapy (NCHT) and investigated the medical records of patients with high-risk PCa who underwen...

Full description

Bibliographic Details
Main Authors: Fumiya Sugino, Keita Nakane, Makoto Kawase, Shota Ueda, Masayuki Tomioka, Yasumichi Takeuchi, Risa Tomioka-Inagawa, Toyohiro Yamada, Sanae Namiki, Naotaka Kumada, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Yuki Tobisawa, Takuya Koie
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Life
Subjects:
high-risk prostate cancer
robot-assisted radical prostatectomy
neoadjuvant chemohormonal therapy
luteinizing hormone-releasing hormone antagonist
tegafur-uracil
Online Access:https://www.mdpi.com/2075-1729/13/5/1072

Internet

https://www.mdpi.com/2075-1729/13/5/1072

Similar Items